Twist Bioscience and Neogene partner for next-generation personalized T cell therapies
Partnership combines Twist’s leadership in DNA synthesis and synthetic biology with Neogene’s expertise in personalized engineered T cell therapies
Partnership combines Twist’s leadership in DNA synthesis and synthetic biology with Neogene’s expertise in personalized engineered T cell therapies
We speak with Dr. Ed Emmott, founder of The Emmott Lab & COVID-19 Mass Spec Coalition member, about his latest research into the disease
New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs
Explore our roundup of key considerations for a successful CRISPR/Cas9 experiment
The Direct assay is validated on a wide range of specimen types, and can be run in parallel with the Simplexa Flu A/B & RSV Direct Gen II assay
Learn about sample contaminant detection, an important step towards nucleic acid quantification
Join us on Thursday, September 24, to learn more about new updates of the NanoDrop One platform
RiboShield RNase Inhibitor complements PCR Biosystems’s range of products to support COVID-19 research and testing
The award money will help to expand Nanotrap Particle manufacturing capacity for COVID-19 testing
Watch this on-demand webinar to learn about the latest approaches in single nucleus transcriptomics and ATAC-Seq
The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel
The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours
Join us on Tuesday, August 18, to learn about the methods used for profiling RNA in COVID-19 samples
Just leave a quick lab product review today for your chance to scoop one of our weekly $100 prizes
Dr. Nallasivam Palanisamy, Henry Ford Cancer Institute, discusses his discovery of the first pseudogene-associated recurrent gene fusion in cancer and the potential for this robust biomarker for application beyond prostate cancer
Find out how collaboration between Pall and key life sciences researchers is helping to innovate and accelerate biologic development
Learn how RNAscope technology was adapted to study plant tissues and gain insights into plant immunity